Identification

Name
Alimemazine
Accession Number
DB01246  (APRD00258)
Type
Small Molecule
Groups
Approved, Vet Approved
Description

A phenothiazine derivative that is used as an antipruritic. [PubChem]

Structure
Thumb
Synonyms
  • Alimemazine
  • Methylpromazine
  • Repeltin
  • Trimeprazine
Product Ingredients
IngredientUNIICASInChI Key
Alimemazine tartrate362NW1LD6Z4330-99-8AJZJIYUOOJLBAU-RNKHSWPKSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Panectyl 2.5 Liq 2.5mg/5mlLiquid2.5 mgOralAventis Pharma Ltd.1960-12-312003-07-22Canada
Panectyl Tab 2.5mgTablet2.5 mgOralErfa Canada 2012 Inc1959-12-31Not applicableCanada
Panectyl Tab 5mgTablet5 mgOralErfa Canada 2012 Inc1959-12-31Not applicableCanada
International/Other Brands
Alimezine / Nedeltran / Panectyl / Theralen / Theralene / Vallergan
Categories
UNII
76H78MJJ52
CAS number
84-96-8
Weight
Average: 298.446
Monoisotopic: 298.150369404
Chemical Formula
C18H22N2S
InChI Key
ZZHLYYDVIOPZBE-UHFFFAOYSA-N
InChI
InChI=1S/C18H22N2S/c1-14(12-19(2)3)13-20-15-8-4-6-10-17(15)21-18-11-7-5-9-16(18)20/h4-11,14H,12-13H2,1-3H3
IUPAC Name
dimethyl[2-methyl-3-(10H-phenothiazin-10-yl)propyl]amine
SMILES
CC(CN(C)C)CN1C2=CC=CC=C2SC2=CC=CC=C12

Pharmacology

Indication

Used to prevent and relieve allergic conditions which cause pruritus (itching) and urticaria (some allergic skin reactions).

Structured Indications
Pharmacodynamics

Trimeprazine (also known as Alimemazine) is a tricyclic antihistamine, similar in structure to the phenothiazine antipsychotics, but differing in the ring-substitution and chain characteristics. Trimeprazine is in the same class of drugs as chlorpromazine (Thorazine) and trifluoperazine (Stelazine); however, unlike the other drugs in this class, trimeprazine is not used clinically as an anti-psychotic. It acts as an anti-histamine, a sedative, and an anti-emetic (anti-nausea). Trimeprazine is used principally as an anti-emetic, to prevent motion sickness or as an anti-histamine in combination with other medications in cough and cold preparations. Tricyclic antihistamines are also structurally-related to the tricyclic antidepressants, explaining the antihistaminergic adverse effects of these two drug classes and also the poor tolerability profile of tricyclic H1-antihistamines.

Mechanism of action

Trimeprazine competes with free histamine for binding at HA-receptor sites. This antagonizes the effects of histamine on HA-receptors, leading to a reduction of the negative symptoms brought on by histamine HA-receptor binding.

TargetActionsOrganism
AHistamine H1 receptor
antagonist
Human
Absorption

Well absorbed in the digestive tract.

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism

Hepatic

Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity

Symptoms of overdose clumsiness or unsteadiness, seizures, severe drowsiness, flushing or redness of face, hallucinations, muscle spasms (especially of neck and back), restlessness, shortness of breath, shuffling walk, tic-like (jerky) movements of head and face, trembling and shaking of hands, and insomnia.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Alimemazine H1-Antihistamine ActionDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetamine2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Alimemazine.Experimental, Illicit
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Alimemazine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Alimemazine.Experimental, Illicit
5'-Deoxy-5'-MethylthioadenosineThe serum concentration of Alimemazine can be increased when it is combined with 5'-Deoxy-5'-Methylthioadenosine.Experimental
AcebutololAlimemazine may increase the hypotensive activities of Acebutolol.Approved
AlaproclateThe risk or severity of adverse effects can be increased when Alimemazine is combined with Alaproclate.Experimental
AlfentanilAlimemazine may increase the hypotensive activities of Alfentanil.Approved, Illicit
AlgeldrateAlgeldrate can cause a decrease in the absorption of Alimemazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental
AlmagateAlmagate can cause a decrease in the absorption of Alimemazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
AlmasilateAlmasilate can cause a decrease in the absorption of Alimemazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental
AloglutamolAloglutamol can cause a decrease in the absorption of Alimemazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
AlphacetylmethadolAlimemazine may increase the hypotensive activities of Alphacetylmethadol.Experimental, Illicit
AlphaprodineAlimemazine may increase the hypotensive activities of Alphaprodine.Illicit
AlprenololAlimemazine may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
AluminiumAluminium can cause a decrease in the absorption of Alimemazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Aluminium acetoacetateAluminium acetoacetate can cause a decrease in the absorption of Alimemazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Aluminium glycinateAluminium glycinate can cause a decrease in the absorption of Alimemazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Aluminum hydroxideAluminum hydroxide can cause a decrease in the absorption of Alimemazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AmodiaquineThe serum concentration of Alimemazine can be increased when it is combined with Amodiaquine.Approved, Investigational
AmoxapineThe risk or severity of adverse effects can be increased when Alimemazine is combined with Amoxapine.Approved
AmphetamineAmphetamine may decrease the sedative activities of Alimemazine.Approved, Illicit
AripiprazoleThe serum concentration of Aripiprazole can be decreased when it is combined with Alimemazine.Approved, Investigational
ArotinololAlimemazine may increase the hypotensive activities of Arotinolol.Approved, Investigational
ArtemetherThe serum concentration of Alimemazine can be increased when it is combined with Artemether.Approved
ArtemisininThe serum concentration of Alimemazine can be increased when it is combined with Artemisinin.Investigational
ArtemotilThe serum concentration of Alimemazine can be increased when it is combined with Artemotil.Experimental
ArtenimolThe serum concentration of Alimemazine can be increased when it is combined with Artenimol.Approved, Investigational
ArtesunateThe serum concentration of Alimemazine can be increased when it is combined with Artesunate.Approved, Investigational
AtenololAlimemazine may increase the hypotensive activities of Atenolol.Approved
AtovaquoneThe serum concentration of Alimemazine can be increased when it is combined with Atovaquone.Approved
BefunololAlimemazine may increase the hypotensive activities of Befunolol.Experimental
BenzphetamineBenzphetamine may decrease the sedative activities of Alimemazine.Approved, Illicit
Benzylpenicilloyl PolylysineAlimemazine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
BetahistineThe therapeutic efficacy of Betahistine can be decreased when used in combination with Alimemazine.Approved
BetaxololAlimemazine may increase the hypotensive activities of Betaxolol.Approved
BevantololAlimemazine may increase the hypotensive activities of Bevantolol.Approved
BezitramideAlimemazine may increase the hypotensive activities of Bezitramide.Experimental, Illicit, Withdrawn
Bismuth SubcitrateBismuth Subcitrate can cause a decrease in the absorption of Alimemazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Bismuth subnitrateBismuth subnitrate can cause a decrease in the absorption of Alimemazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
BisoprololAlimemazine may increase the hypotensive activities of Bisoprolol.Approved
BopindololAlimemazine may increase the hypotensive activities of Bopindolol.Approved
BucindololAlimemazine may increase the hypotensive activities of Bucindolol.Investigational
BufuralolAlimemazine may increase the hypotensive activities of Bufuralol.Experimental, Investigational
BupranololAlimemazine may increase the hypotensive activities of Bupranolol.Approved
BuprenorphineAlimemazine may increase the hypotensive activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
ButorphanolAlimemazine may increase the hypotensive activities of Butorphanol.Approved, Illicit, Vet Approved
Calcium CarbonateCalcium Carbonate can cause a decrease in the absorption of Alimemazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium silicateCalcium silicate can cause a decrease in the absorption of Alimemazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
CarfentanilAlimemazine may increase the hypotensive activities of Carfentanil.Illicit, Investigational, Vet Approved
CarteololAlimemazine may increase the hypotensive activities of Carteolol.Approved
CarvedilolAlimemazine may increase the hypotensive activities of Carvedilol.Approved, Investigational
CeliprololAlimemazine may increase the hypotensive activities of Celiprolol.Approved, Investigational
ChloroquineThe serum concentration of Alimemazine can be increased when it is combined with Chloroquine.Approved, Vet Approved
ChlorphentermineChlorphentermine may decrease the sedative activities of Alimemazine.Illicit, Withdrawn
ChlorproguanilThe serum concentration of Alimemazine can be increased when it is combined with Chlorproguanil.Investigational
CitalopramThe risk or severity of adverse effects can be increased when Alimemazine is combined with Citalopram.Approved
ClomipramineThe risk or severity of adverse effects can be increased when Alimemazine is combined with Clomipramine.Approved, Vet Approved
CloranololAlimemazine may increase the hypotensive activities of Cloranolol.Experimental
CodeineAlimemazine may increase the hypotensive activities of Codeine.Approved, Illicit
Cycloguanil embonateThe serum concentration of Alimemazine can be increased when it is combined with Cycloguanil embonate.Experimental
DapoxetineThe risk or severity of adverse effects can be increased when Alimemazine is combined with Dapoxetine.Investigational
DapsoneThe serum concentration of Alimemazine can be increased when it is combined with Dapsone.Approved, Investigational
DextroamphetamineDextroamphetamine may decrease the sedative activities of Alimemazine.Approved, Illicit
DextromoramideAlimemazine may increase the hypotensive activities of Dextromoramide.Experimental, Illicit
DextropropoxypheneAlimemazine may increase the hypotensive activities of Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DezocineAlimemazine may increase the hypotensive activities of Dezocine.Approved, Investigational
DiethylpropionDiethylpropion may decrease the sedative activities of Alimemazine.Approved, Illicit
DihydrocodeineAlimemazine may increase the hypotensive activities of Dihydrocodeine.Approved, Illicit
DihydroetorphineAlimemazine may increase the hypotensive activities of Dihydroetorphine.Experimental, Illicit
DihydromorphineAlimemazine may increase the hypotensive activities of Dihydromorphine.Experimental, Illicit
DiphenoxylateAlimemazine may increase the hypotensive activities of Diphenoxylate.Approved, Illicit
DoxycyclineThe serum concentration of Alimemazine can be increased when it is combined with Doxycycline.Approved, Investigational, Vet Approved
DPDPEAlimemazine may increase the hypotensive activities of DPDPE.Investigational
EpanololAlimemazine may increase the hypotensive activities of Epanolol.Experimental
EscitalopramThe risk or severity of adverse effects can be increased when Alimemazine is combined with Escitalopram.Approved, Investigational
EsmololAlimemazine may increase the hypotensive activities of Esmolol.Approved
EthylmorphineAlimemazine may increase the hypotensive activities of Ethylmorphine.Approved, Illicit
EtorphineAlimemazine may increase the hypotensive activities of Etorphine.Illicit, Vet Approved
FenfluramineThe risk or severity of adverse effects can be increased when Alimemazine is combined with Fenfluramine.Illicit, Investigational, Withdrawn
FentanylAlimemazine may increase the hypotensive activities of Fentanyl.Approved, Illicit, Investigational, Vet Approved
FluoxetineThe risk or severity of adverse effects can be increased when Alimemazine is combined with Fluoxetine.Approved, Vet Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Alimemazine is combined with Fluvoxamine.Approved, Investigational
GepefrineGepefrine may decrease the sedative activities of Alimemazine.Experimental
HalofantrineThe serum concentration of Alimemazine can be increased when it is combined with Halofantrine.Approved
HeroinAlimemazine may increase the hypotensive activities of Heroin.Approved, Illicit, Investigational
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Alimemazine.Approved, Investigational
HydrocodoneAlimemazine may increase the hypotensive activities of Hydrocodone.Approved, Illicit
HydromorphoneAlimemazine may increase the hypotensive activities of Hydromorphone.Approved, Illicit
HydrotalciteHydrotalcite can cause a decrease in the absorption of Alimemazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental, Investigational
HydroxyamphetamineHydroxyamphetamine may decrease the sedative activities of Alimemazine.Approved
HydroxychloroquineThe serum concentration of Alimemazine can be increased when it is combined with Hydroxychloroquine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Alimemazine is combined with Indalpine.Investigational, Withdrawn
IndenololAlimemazine may increase the hypotensive activities of Indenolol.Withdrawn
Iofetamine I-123Iofetamine I-123 may decrease the sedative activities of Alimemazine.Approved
KetobemidoneAlimemazine may increase the hypotensive activities of Ketobemidone.Approved, Investigational
LabetalolAlimemazine may increase the hypotensive activities of Labetalol.Approved
LandiololAlimemazine may increase the hypotensive activities of Landiolol.Investigational
LevobunololAlimemazine may increase the hypotensive activities of Levobunolol.Approved
Levomethadyl AcetateAlimemazine may increase the hypotensive activities of Levomethadyl Acetate.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Alimemazine is combined with Levomilnacipran.Approved
LevorphanolAlimemazine may increase the hypotensive activities of Levorphanol.Approved
LisdexamfetamineLisdexamfetamine may decrease the sedative activities of Alimemazine.Approved, Investigational
LofentanilAlimemazine may increase the hypotensive activities of Lofentanil.Illicit
LumefantrineThe serum concentration of Alimemazine can be increased when it is combined with Lumefantrine.Approved
MagaldrateMagaldrate can cause a decrease in the absorption of Alimemazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Withdrawn
Magnesium HydroxideMagnesium Hydroxide can cause a decrease in the absorption of Alimemazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium oxideMagnesium oxide can cause a decrease in the absorption of Alimemazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium peroxideMagnesium peroxide can cause a decrease in the absorption of Alimemazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Magnesium silicateMagnesium silicate can cause a decrease in the absorption of Alimemazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental
Magnesium TrisilicateMagnesium Trisilicate can cause a decrease in the absorption of Alimemazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
MefloquineThe serum concentration of Alimemazine can be increased when it is combined with Mefloquine.Approved
MephedroneMephedrone may decrease the sedative activities of Alimemazine.Investigational
MephentermineMephentermine may decrease the sedative activities of Alimemazine.Approved
MepindololAlimemazine may increase the hypotensive activities of Mepindolol.Experimental
MeptazinolAlimemazine may increase the hypotensive activities of Meptazinol.Experimental
MethadoneAlimemazine may increase the hypotensive activities of Methadone.Approved
Methadyl AcetateAlimemazine may increase the hypotensive activities of Methadyl Acetate.Approved, Illicit
MethamphetamineMethamphetamine may decrease the sedative activities of Alimemazine.Approved, Illicit
MethoxyphenamineMethoxyphenamine may decrease the sedative activities of Alimemazine.Experimental
MetipranololAlimemazine may increase the hypotensive activities of Metipranolol.Approved
MetoprololAlimemazine may increase the hypotensive activities of Metoprolol.Approved, Investigational
Midomafetamine3,4-Methylenedioxymethamphetamine may decrease the sedative activities of Alimemazine.Experimental, Illicit, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Alimemazine is combined with Milnacipran.Approved
MizoribineThe serum concentration of Alimemazine can be increased when it is combined with Mizoribine.Investigational
MMDAMMDA may decrease the sedative activities of Alimemazine.Experimental, Illicit
MorphineAlimemazine may increase the hypotensive activities of Morphine.Approved, Investigational
NadololAlimemazine may increase the hypotensive activities of Nadolol.Approved
NalbuphineAlimemazine may increase the hypotensive activities of Nalbuphine.Approved
NicomorphineAlimemazine may increase the hypotensive activities of Nicomorphine.Experimental
NormethadoneAlimemazine may increase the hypotensive activities of Normethadone.Approved, Illicit
OlanzapineThe risk or severity of adverse effects can be increased when Alimemazine is combined with Olanzapine.Approved, Investigational
OpiumAlimemazine may increase the hypotensive activities of Opium.Approved, Illicit
OxprenololAlimemazine may increase the hypotensive activities of Oxprenolol.Approved
OxycodoneAlimemazine may increase the hypotensive activities of Oxycodone.Approved, Illicit, Investigational
OxymorphoneAlimemazine may increase the hypotensive activities of Oxymorphone.Approved, Investigational, Vet Approved
ParoxetineThe risk or severity of adverse effects can be increased when Alimemazine is combined with Paroxetine.Approved, Investigational
PenbutololAlimemazine may increase the hypotensive activities of Penbutolol.Approved, Investigational
PentazocineAlimemazine may increase the hypotensive activities of Pentazocine.Approved, Vet Approved
PethidineAlimemazine may increase the hypotensive activities of Pethidine.Approved
PhenazocineAlimemazine may increase the hypotensive activities of Phenazocine.Experimental
PhenoperidineAlimemazine may increase the hypotensive activities of Phenoperidine.Experimental
PhenterminePhentermine may decrease the sedative activities of Alimemazine.Approved, Illicit
PindololAlimemazine may increase the hypotensive activities of Pindolol.Approved
PiritramideAlimemazine may increase the hypotensive activities of Piritramide.Investigational
PractololAlimemazine may increase the hypotensive activities of Practolol.Approved
PrimaquineThe serum concentration of Alimemazine can be increased when it is combined with Primaquine.Approved
ProguanilThe serum concentration of Alimemazine can be increased when it is combined with Proguanil.Approved
PropranololAlimemazine may increase the hypotensive activities of Propranolol.Approved, Investigational
PseudoephedrinePseudoephedrine may decrease the sedative activities of Alimemazine.Approved
PyrimethamineThe serum concentration of Alimemazine can be increased when it is combined with Pyrimethamine.Approved, Vet Approved
PyronaridineThe serum concentration of Alimemazine can be increased when it is combined with Pyronaridine.Investigational
QuinacrineThe serum concentration of Alimemazine can be increased when it is combined with Quinacrine.Approved, Investigational
QuinidineThe serum concentration of Alimemazine can be increased when it is combined with Quinidine.Approved
QuinineThe serum concentration of Alimemazine can be increased when it is combined with Quinine.Approved
RadicicolThe serum concentration of Alimemazine can be increased when it is combined with Radicicol.Experimental
RemifentanilAlimemazine may increase the hypotensive activities of Remifentanil.Approved
RitobegronRitobegron may decrease the sedative activities of Alimemazine.Investigational
SaxagliptinThe serum concentration of Saxagliptin can be decreased when it is combined with Alimemazine.Approved
SertralineThe risk or severity of adverse effects can be increased when Alimemazine is combined with Sertraline.Approved
SinefunginThe serum concentration of Alimemazine can be increased when it is combined with Sinefungin.Experimental
SotalolAlimemazine may increase the hypotensive activities of Sotalol.Approved
SufentanilAlimemazine may increase the hypotensive activities of Sufentanil.Approved, Investigational
SulfadoxineThe serum concentration of Alimemazine can be increased when it is combined with Sulfadoxine.Approved, Investigational
SulfametopyrazineThe serum concentration of Alimemazine can be increased when it is combined with Sulfametopyrazine.Approved, Withdrawn
tafenoquineThe serum concentration of Alimemazine can be increased when it is combined with tafenoquine.Investigational
TalinololAlimemazine may increase the hypotensive activities of Talinolol.Investigational
TapentadolAlimemazine may increase the hypotensive activities of Tapentadol.Approved
TertatololAlimemazine may increase the hypotensive activities of Tertatolol.Experimental
ThiopentalThe risk or severity of adverse effects can be increased when Alimemazine is combined with Thiopental.Approved, Vet Approved
TilidineAlimemazine may increase the hypotensive activities of Tilidine.Experimental
TimololAlimemazine may increase the hypotensive activities of Timolol.Approved
TramadolAlimemazine may increase the hypotensive activities of Tramadol.Approved, Investigational
TrazodoneThe risk or severity of adverse effects can be increased when Alimemazine is combined with Trazodone.Approved, Investigational
TrimethoprimThe serum concentration of Alimemazine can be increased when it is combined with Trimethoprim.Approved, Vet Approved
VilazodoneThe risk or severity of adverse effects can be increased when Alimemazine is combined with Vilazodone.Approved
VortioxetineThe risk or severity of adverse effects can be increased when Alimemazine is combined with Vortioxetine.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Alimemazine is combined with Zimelidine.Withdrawn
Food Interactions
Not Available

References

General References
Not Available
External Links
Human Metabolome Database
HMDB15376
KEGG Compound
C07172
PubChem Compound
5574
PubChem Substance
46508449
ChemSpider
5373
BindingDB
50062261
ChEBI
9725
ChEMBL
CHEMBL829
Therapeutic Targets Database
DAP001077
PharmGKB
PA164744009
ATC Codes
R06AD01 — Alimemazine
AHFS Codes
  • 04:04.12 — Phenothiazine Derivatives

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Dosage forms
FormRouteStrength
LiquidOral2.5 mg
TabletOral2.5 mg
TabletOral5 mg
Prices
Unit descriptionCostUnit
Panectyl 5 mg Tablet0.37USD tablet
Panectyl 2.5 mg Tablet0.3USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)68 °CPhysProp
boiling point (°C)150-175 °C at 3.00E-01 mm HgPhysProp
water solubility0.942 mg/LNot Available
logP4.71HANSCH,C ET AL. (1995)
pKa9.05SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility0.00835 mg/mLALOGPS
logP4.82ALOGPS
logP4.41ChemAxon
logS-4.6ALOGPS
pKa (Strongest Basic)9.42ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area6.48 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity93.37 m3·mol-1ChemAxon
Polarizability34.83 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9738
Blood Brain Barrier+0.9886
Caco-2 permeable+0.7965
P-glycoprotein substrateSubstrate0.6637
P-glycoprotein inhibitor IInhibitor0.6501
P-glycoprotein inhibitor IIInhibitor0.7613
Renal organic cation transporterNon-inhibitor0.5286
CYP450 2C9 substrateNon-substrate0.7739
CYP450 2D6 substrateSubstrate0.748
CYP450 3A4 substrateSubstrate0.5224
CYP450 1A2 substrateNon-inhibitor0.804
CYP450 2C9 inhibitorNon-inhibitor0.9195
CYP450 2D6 inhibitorInhibitor0.9381
CYP450 2C19 inhibitorNon-inhibitor0.8436
CYP450 3A4 inhibitorNon-inhibitor0.6702
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.6487
Ames testNon AMES toxic0.7784
CarcinogenicityNon-carcinogens0.9034
BiodegradationNot ready biodegradable0.9968
Rat acute toxicity3.1217 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9819
hERG inhibition (predictor II)Inhibitor0.818
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Download (7.83 KB)
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
GC-MS Spectrum - EI-BGC-MSsplash10-0a4i-9010000000-3652afb69d877d9e3ef5
GC-MS Spectrum - EI-BGC-MSsplash10-0a4i-9240000000-3d6ddecfeef1ce4ea2a2
GC-MS Spectrum - CI-BGC-MSsplash10-0002-1192000000-93fd466d9dd2ccc3c679
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenothiazines. These are polycyclic aromatic compounds containing a phenothiazine moiety, which is a linear tricyclic system that consists of a two benzene rings joined by a para-thiazine ring.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Benzothiazines
Sub Class
Phenothiazines
Direct Parent
Phenothiazines
Alternative Parents
Alkyldiarylamines / Diarylthioethers / Benzenoids / 1,4-thiazines / Trialkylamines / Azacyclic compounds / Organopnictogen compounds / Hydrocarbon derivatives
Substituents
Phenothiazine / Alkyldiarylamine / Diarylthioether / Aryl thioether / Tertiary aliphatic/aromatic amine / Para-thiazine / Benzenoid / Tertiary amine / Tertiary aliphatic amine / Thioether
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
phenothiazines (CHEBI:9725)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Histamine receptor activity
Specific Function
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamin...
Gene Name
HRH1
Uniprot ID
P35367
Uniprot Name
Histamine H1 receptor
Molecular Weight
55783.61 Da
References
  1. Santos DE, Liu GJ, Takeuchi H: Blockers for excitatory effects of achatin-I, a tetrapeptide having a D-phenylalanine residue, on a snail neurone. Eur J Pharmacol. 1995 Jan 16;272(2-3):231-9. [PubMed:7713167]
  2. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Drug created on June 13, 2005 07:24 / Updated on November 13, 2017 21:49